research use only
Cat.No.S8547
| Related Targets | EGFR VEGFR PDGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit |
|---|---|
| Other FGFR Inhibitors | PD173074 AZD4547 (Fexagratinib) BLU9931 Futibatinib (TAS-120) LY2874455 H3B-6527 PD-166866 Fisogatinib (BLU-554) Zoligratinib (Debio-1347) SSR128129E |
|
In vitro |
DMSO
: 8 mg/mL
(17.14 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 466.56 | Formula | C23H26N6O3S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1443530-05-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | BAY-1163877 | SMILES | CC1=CC2=C(C(=C1)OC)SC(=C2)C3=C4C(=NC=NN4C(=C3COC)CN5CCNC(=O)C5)N | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
FGFR2
<1 nM
FGFR4
1.2 nM
FGFR1
1.8 nM
FGFR3
9.2 nM
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2026-07-31)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04595747 | ACTIVE_NOT_RECRUITING | Locally Advanced Gastrointestinal Stromal Tumor; Locally Advanced Sarcoma; Metastatic Gastrointestinal Stromal Tumor; Metastatic Sarcoma; Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8; Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8; Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8; Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8 |
National Cancer Institute (NCI) |
2021-05-03 | PHASE2 |
| NCT04483505 | COMPLETED | Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast |
Fundacion CRIS de Investigación para Vencer el Cáncer |
2020-11-25 | PHASE1 |
| NCT03762122 | TERMINATED | Squamous-cell Non-small Cell Lung Cancer |
Swiss Cancer Institute |
2019-07-25 | PHASE2 |
| NCT03473756 | COMPLETED | Urothelial Carcinoma |
Bayer |
2018-05-15 | PHASE1 |
| NCT04125693 | COMPLETED | Cancer |
Bayer |
2019-10-30 | PHASE2 |
| NCT03517956 | COMPLETED | Advanced or Metastatic Solid Tumor |
Bayer |
2018-07-25 | PHASE1 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.